Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 5
1967 2
1968 6
1969 3
1970 6
1971 10
1972 7
1973 8
1974 7
1975 10
1976 18
1977 23
1978 10
1979 14
1980 12
1981 13
1982 11
1983 9
1984 9
1985 8
1986 11
1987 12
1988 11
1989 8
1990 12
1991 13
1992 5
1993 5
1994 14
1995 10
1996 12
1997 13
1998 9
1999 11
2000 19
2001 11
2002 21
2003 31
2004 22
2005 31
2006 28
2007 22
2008 28
2009 40
2010 45
2011 29
2012 36
2013 59
2014 61
2015 58
2016 50
2017 49
2018 39
2019 31
2020 36
2021 35
2022 31
2023 17
2024 34
2025 32
2026 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,126 results

Results by year

Filters applied: . Clear all
Page 1
Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial.
Lee CJ, Ihm SH, Shin DH, Jeong JO, Kim JH, Chun KH, Ryu J, Lee HY, Choi S, Lee EM, Choi JH, Kim KI, Shin J, Pyun WB, Kim DH, Park S, Williams B. Lee CJ, et al. JAMA. 2025 Jun 17;333(23):2073-2082. doi: 10.1001/jama.2025.5129. JAMA. 2025. PMID: 40366680 Free PMC article. Clinical Trial.
IMPORTANCE: Amiloride has been proposed as an alternative to spironolactone for treating resistant hypertension. However, no randomized clinical trials have compared the efficacy of spironolactone and amiloride in patients with resistant hypertension. ...There were …
IMPORTANCE: Amiloride has been proposed as an alternative to spironolactone for treating resistant hypertension. However, no randomiz …
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. Pitt B, et al. N Engl J Med. 1999 Sep 2;341(10):709-17. doi: 10.1056/NEJM199909023411001. N Engl J Med. 1999. PMID: 10471456 Free article. Clinical Trial.
A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo. The primary end point was death from all causes. RESULTS: The trial was discontinued early, after a mean follow-up period of 24 months, because an interim a …
A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo. The primary end …
Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study.
Dréno B, Nguyen JM, Hainaut E, Machet L, Leccia MT, Beneton N, Claudel JP, Célérier P, Le Moigne M, Le Naour S, Vrignaud F, Poinas A, Dert C, Boisrobert A, Flet L, Korner S, Khammari A. Dréno B, et al. Acta Derm Venereol. 2024 Feb 21;104:adv26002. doi: 10.2340/actadv.v104.26002. Acta Derm Venereol. 2024. PMID: 38380975 Free PMC article. Clinical Trial.
AFAST and ECLA scores, as well as lesion counts always improved more with spironolactone. Patients' quality of life was better with spironolactone at month 4 and month 6. Spironolactone was very well tolerated. This is the first study to show that, in female …
AFAST and ECLA scores, as well as lesion counts always improved more with spironolactone. Patients' quality of life was better with …
Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.
Hobbs FDR, McManus RJ, Taylor CJ, Jones NR, Rahman JK, Wolstenholme J, Kim S, Kwon J, Jones L, Hirst JA, Yu LM, Mort S; BARACK-D Investigators; BARACK-D Investigators; Regional coordinating centre teams. Hobbs FDR, et al. Nat Med. 2024 Dec;30(12):3634-3645. doi: 10.1038/s41591-024-03263-5. Epub 2024 Sep 30. Nat Med. 2024. PMID: 39349629 Free PMC article. Clinical Trial.
Two-thirds of participants randomized to spironolactone stopped treatment within 6 months, predominantly because they met prespecified safety stop criteria. ...Spironolactone should not be used for people with stage 3b CKD without another explicit treatment indicati …
Two-thirds of participants randomized to spironolactone stopped treatment within 6 months, predominantly because they met prespecifie …
Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial.
Santer M, Lawrence M, Renz S, Eminton Z, Stuart B, Sach TH, Pyne S, Ridd MJ, Francis N, Soulsby I, Thomas K, Permyakova N, Little P, Muller I, Nuttall J, Griffiths G, Thomas KS, Layton AM; SAFA trial investigators. Santer M, et al. BMJ. 2023 May 16;381:e074349. doi: 10.1136/bmj-2022-074349. BMJ. 2023. PMID: 37192767 Free PMC article. Clinical Trial.
INTERVENTIONS: Participants were randomly assigned (1:1) to either 50 mg/day spironolactone or matched placebo until week six, increasing to 100 mg/day spironolactone or placebo until week 24. ...Spironolactone is a useful alternative to oral antibiotics for …
INTERVENTIONS: Participants were randomly assigned (1:1) to either 50 mg/day spironolactone or matched placebo until week six, increa …
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, Ma J, White WB, Williams B. Agarwal R, et al. Lancet. 2019 Oct 26;394(10208):1540-1550. doi: 10.1016/S0140-6736(19)32135-X. Epub 2019 Sep 15. Lancet. 2019. PMID: 31533906 Clinical Trial.
However, the use of spironolactone in patients with chronic kidney disease can be restricted by hyperkalaemia. ...Dose titrations were permitted after 1 week (patiromer) and 3 weeks (spironolactone). The primary endpoint was the between-group difference at week 12 i …
However, the use of spironolactone in patients with chronic kidney disease can be restricted by hyperkalaemia. ...Dose titrations wer …
[The TOPCAT study].
Boccanelli A, Pulignano G. Boccanelli A, et al. G Ital Cardiol (Rome). 2014 Oct;15(10):521-6. doi: 10.1714/1672.18298. G Ital Cardiol (Rome). 2014. PMID: 25424015 Clinical Trial. Italian. No abstract available.
Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT.
Santer M, Lawrence M, Pyne S, Renz S, Stuart BL, Sach T, Ridd M, Thomas KS, Nuttall J, Permyakova N, Eminton Z, Francis N, Little P, Muller I, Soulsby I, Thomas K, Griffiths G, Layton AM. Santer M, et al. Health Technol Assess. 2024 Sep;28(56):1-86. doi: 10.3310/MYJT6804. Health Technol Assess. 2024. PMID: 39268864 Free PMC article. Clinical Trial.
INTERVENTIONS: Participants were randomised 1 : 1, using an independent web-based procedure, to either 50 mg/day spironolactone or matched placebo until week 6, increasing to 100 mg/day spironolactone or matched placebo until week 24. ...Mean scores at week 12 were …
INTERVENTIONS: Participants were randomised 1 : 1, using an independent web-based procedure, to either 50 mg/day spironolactone or ma …
Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT.
Hobbs FDR, McManus R, Taylor C, Jones N, Rahman J, Wolstenholme J, Jones L, Hirst J, Mort S, Yu LM; BARACK-D Investigators. Hobbs FDR, et al. Health Technol Assess. 2025 Mar;29(5):1-130. doi: 10.3310/PYFT6977. Health Technol Assess. 2025. PMID: 40106397 Free PMC article. Clinical Trial.
OBJECTIVES: To determine the effect of low-dose spironolactone on mortality and cardiovascular outcomes in people with chronic kidney disease stage 3b. ...Two-thirds of participants randomised to spironolactone stopped treatment within six months because they met pr …
OBJECTIVES: To determine the effect of low-dose spironolactone on mortality and cardiovascular outcomes in people with chronic kidney …
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Pfeffer MA, et al. Circulation. 2015 Jan 6;131(1):34-42. doi: 10.1161/CIRCULATIONAHA.114.013255. Epub 2014 Nov 18. Circulation. 2015. PMID: 25406305 Clinical Trial.
Hyperkalemia and doubling of creatinine were more likely and hypokalemia was less likely in patients receiving spironolactone in the Americas with no significant treatment effects in Russia/Georgia. All clinical event rates were markedly lower in Russia/Georgia, and there …
Hyperkalemia and doubling of creatinine were more likely and hypokalemia was less likely in patients receiving spironolactone in the …
1,126 results